Suggested remit: To appraise the clinical and cost effectiveness of treatments for non-small-cell lung cancer.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Scoping commencing
- Process:
- Pathways Pilot
- ID number:
- 6234
Project Team
- Project lead
- Celia Mayers
Email enquiries
If you have any queries please email TATeam6@nice.org.uk
- External Assessment Group:
- Bristol Technology Assessment Group, University of Bristol
Stakeholders
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- ALK Positive UK
- EGFR Positive UK
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- British Thoracic Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Pathway companies:
- AbbVie
- Amarox (erlotinib) – confidentiality agreement not signed, not participating
- AstraZeneca (durvalumab, osimertinib)
- Boehringer Ingelheim (afatinib) – confidentiality agreement not signed, not participating
- Cipla EU (gefitinib) – confidentiality agreement not signed, not participating
- Daiichi Sankyo (trastuzumab deruxtecan)
- GlaxoSmithKline
- Johnson & Johnson Innovative Medicine (amivantamab)
- Merck (tepotinib)
- Novartis (ceritinib, dabrafenib, trametinib)
- Pfizer (crizotinib, dacomitinib, lorlatinib) – confidentiality agreement not signed, not participating
- Regeneron (cemiplimab) – confidentiality agreement not signed, not participating
- Roche (alectinib)
- Takeda (brigatinib)
- Comparator companies:
- Amgen (sotorasib)
- Aspire Pharma (pemetrexed) – confidentiality agreement not signed, not participating
- Bayer (laroctrectinib)
- Boehringer Ingelheim (nintedanib) – confidentiality agreement not signed, not participating
- Bristol Myers Squibb (nivolumab, paclitaxel)
- Celltrion Healthcare UK (bevacizumab) – confidentiality agreement not signed, not participating
- Dr Reddy’s Laboratories (pemetrexed) – confidentiality agreement not signed, not participating
- Eli Lilly (selpercatinib, pemetrexed)
- Genus Pharmaceuticals (pemetrexed) – confidentiality agreement not signed, not participating
- Hospira UK (cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed) – confidentiality agreement not signed, not participating
- Inceptua (paclitaxel) – confidentiality agreement not signed, not participating
- Medac (oxaliplatin, vinorelbine) – confidentiality agreement not signed, not participating
- Merck Sharp & Dohme UK (pembrolizumab)
- Mylan (pemetrexed) – confidentiality agreement not signed, not participating
- Organon Pharma (bevacizumab) – confidentiality agreement not signed, not participating
- Pfizer (pemetrexed, bevacizumab) – confidentiality agreement not signed, not participating
- Pierre Fabre (vinorelbine) – confidentiality agreement not signed, not participating
- Roche (atezolizumab, bevacizumab entrectinib)
- Sandoz (cisplatin, pemetrexed) – confidentiality agreement not signed, not participating
- Sanofi
- Seacross Pharmaceuticals (oxaliplatin, docetaxel, paclitaxel) – confidentiality agreement not signed, not participating
- Takeda (mobocertinib)
- Thornton and Ross (bevacizumab) – confidentiality agreement not signed, not participating
- Zentiva (bevacizumab) – confidentiality agreement not signed, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 February 2024 | Following feedback on the pilot projects for the pathway approach, NICE is currently assessing what principles and lessons of the pathway pilots it will incorporate into the Single Technology Appraisal (STA) process. Considering the re-focus to align with ongoing strategic ambitions and there being no live topics in the NSCLC pilot, the committee meeting scheduled for 27 March 2024 will not be going ahead. Production of the NSCLC model continues, and the model and a model report will be published later in 2024 on this webpage. The process statement will remain on this webpage, for transparency about the intended pathway approach but will no longer be used. |
| 15 February 2024 | Discontinued |
| 03 October 2023 | Stakeholder workshop |
| 01 August 2023 | Invitation to participate |
| 01 August 2023 | Any companies with a medicine that meets the eligibility and selection criteria for technology appraisal guidance (see sections 4.1.4 and 6.2.1 of the manual) can request to become a NSCLC pathway company stakeholder. Companies with medicines which are expected to get appropriate regulatory approval beyond 24 months are also eligible to request to become a pathway stakeholder. For more information please email TAteam6@nice.org.uk. |
| 21 July 2023 | The scope of the first iteration of the NSCLC pathway will focus on development of the evidence synthesis of currently available data and the core model development. Opportunities for stakeholder development will be shared in due course. |
| 24 April 2023 (12:30) | Scoping workshop |
| 27 February 2023 - 27 March 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6234 |
| 27 February 2023 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual